Robert Thompson and Joseph de Vivo have joined Quantum Surgical’s Board of Directors

Montpellier – April-13th-2023

Quantum Surgical, the Medical Robotic company dedicated to the curative and early treatment of cancers, has appointed Robert Thompson and Joseph de Vivo and on its Board of Directors as Independent Board Members.

Robert Thompson (Bob) is an accomplished marketing and business development leader and brings Quantum Surgical his experience in product development and commercialization in the medtech industry. He previously served as President-Ultrasound Siemens Healthineers, senior leadership positions at GE Healthcare and medical device start-ups.

“I am excited to join such a talented and visionary team. The innovative solutions developed by Quantum Surgical have the potential to  transform cancer treatments by bringing a new standard of minimally invasive care  of cancer patients worldwide  ” says Robert Thompson.

Joseph de Vivo brings over 30 years of experience in medical device, robotics and digital health industries. He was most recently Executive Chairman of Caption Health, President of Hospitals and Health Systems for Teladoc Health and CEO of InTouch Health. He previously served as CEO of Angiodynamics and President of Smith & Nephew Orthopedics. Mr DeVivo currently serves as the Treasurer of the American Telemedicine Association and on the Board of Governors for St Jude Children’s Research Hospital.

“The arrival of Robert and Joseph, two experienced healthtech leaders among our Board Members is a real opportunity for Quantum Surgical and will directly serve our strategy and our development, particularly in the United States”, said Bertin Nahum, CEO and Co-Founder of Quantum Surgical.

————————————————————————————————————————————–

About Quantum Surgical

Co-founded in 2017 by Bertin Nahum, Quantum Surgical is a leading innovative French medical robotic company based out of Montpellier- France, with an international reach.

Quantum Surgical develops intelligent solutions capable of responding to complex and widespread medical challenges. Its Epione^® robotic platform for percutaneous ablation is dedicated to the curative and early treatment of cancers. It is currently the only robotic platform capable of assisting practitioners in planning, targeting and performing percutaneous ablation procedures on cancerous tumors, particularly those located in the abdomen.

Quantum Surgical thus offers a new approach to cancer treatment by enabling standardization of care, and therefore more patients will benefit from innovative, better targeted and less aggressive treatments.

For more information, please visit Quantum Surgical and follow our LinkedIn and Twitter accounts.